Bank of New York Mellon’s Context Therapeutics CNTX Stock Holding History

Bank of New York Mellon’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$60.6K	Buy	+109,362	New	+$222K	﹤0.01%	4229

Other funds holding CNTX

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

Bank of New York Mellon's CNTX Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Context Therapeutics (CNTX) in Q2 2026: 109,362 shares worth $60.6K. The stake represents ﹤0.01% of the portfolio and ranks #4229 among its holdings.

28 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

Bank of New York Mellon held 109,362 shares of Context Therapeutics worth $60.6K as of Q2 2026.
Context Therapeutics was a new Bank of New York Mellon position in Q2 2026.
Context Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #4229 holding.
28 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.